- With Humira's LOE looming in 2023, AbbVie stands to lose billions of dollars in revenues.
- Estimating Humira's likely losses to biosimilars in the US in 2023 and onward is more art than science, albeit there are plentiful clues to work with.
- AbbVie's long-term guidance around its US Humira LOE is encouraging but questions linger.
- AbbVie's two burgeoning immunology therapies, Skyrizi and Rinvoq, along with its newly acquired aesthetics franchise, are lining up to help shoulder the missing revenues.
For further details see:
AbbVie: Beyond Humira, Framing A Bright Future